The Supreme Court has decided that the Food & Drug Administration may reinstate its safety policy for chemical-abortion drugs. Since the drug was first approved in 2000, the FDA has required that women obtain it in person rather than via telemedicine, a provision meant to ensure that women are in touch with a health-care professional and able to obtain follow-up treatment in the event of complications.